Context of change - X inactivation and disease

EMBO Molecular Medicine

Volumn 2, Issue 1, 2010, Pages 6-15

  Agrelo, Ruben ^a   Wutz, Anton ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Cancer; Chromatin; Epigenetics; X inactivation; Xist RNA

Indexed keywords

DNA METHYLTRANSFERASE; I KAPPA B KINASE GAMMA; POLYCOMB GROUP PROTEIN;

ADULT; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMATIN; EPIGENETICS; GENETIC REGULATION; GENOME IMPRINTING; HUMAN; LEUKEMIA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; THALASSEMIA; X CHROMOSOME; X CHROMOSOME INACTIVATION; X CHROMOSOME LINKED DISORDER;

ANIMALS; EMBRYO, MAMMALIAN; EPIGENESIS, GENETIC; FEMALE; GENES, X-LINKED; HUMANS; MATRIX ATTACHMENT REGION BINDING PROTEINS; NEOPLASMS; STEM CELLS; X CHROMOSOME; X CHROMOSOME INACTIVATION;

EID: 77953679543     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.200900053     Document Type: Review

References (86)

1. Agrelo R, Souabni A, Novatchkova M, Haslinger C, Leeb M, Komnenovic V, Kishimoto H, Gresh L, Kohwi-Shigematsu T, Kenner L, et al (2009) SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell 16: 507-516
2. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) RETT syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23: 185-188
3. Anderson-Cohen M, Holland SM, Kuhns DB, Fleisher TA, Ding L, Brenner S, Malech HL, Roesler J (2003) Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation. Clin Immunol (Orlando, FL) 109: 308-317
4. Archer H, Evans J, Leonard H, Colvin L, Ravine D, Christodoulou J, Williamson S, Charman T, Bailey ME, Sampson J, et al (2007) Correlation between clinical severity in patients with RETT syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. J Med Genet 44: 148-152
5. Bassell GJ, Warren ST (2008) Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60: 201-214
6. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507
7. Blewitt ME, Gendrel AV, Pang Z, Sparrow DB, Whitelaw N, CraigJM, Apedaile A, Hilton DJ, Dunwoodie SL, Brockdorff N, et al (2008) SmcHD1, containing a structural-maintenance-of-chromosomes hinge domain, has a critical role in X inactivation. Nat Genet 40: 663-669
8. Borsani G,Tonlorenzi R,Simmler MC, Dandolo L, Arnaud D, Capra V, Grompe M, Pizzuti A, Muzny D, Lawrence C, et al (1991) Characterization of a murine gene expressed from the inactive X chromosome. Nature 351: 325-329
9. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, Otte AP, PradelJ, MuchardtC, Sieweke M, Duprez E (2009)The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 23: 1195-1206
10. Brockdorff N (2009) SAT in silence. Dev Cell 16: 483-484
11. Brockdorff N, Ashworth A, Kay GF, Cooper P, Smith S, McCabe VM, Norris DP, Penny GD, Patel D, Rastan S (1991) Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. Nature 351:329-331
12. Brown CJ, Ballabio A, RupertJL, Lafreniere RG, Grompe M,Tonlorenzi R, Willard HF (1991) A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 349: 38-44
13. Brown CJ, Willard HF (1994) The human X-inactivation centre is not required for maintenance of X-chromosome inactivation. Nature 368: 154-156
14. Cai S, Lee CC, Kohwi-Shigematsu T (2006) SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet 38: 1278-1288
15. Chahrour M, Zoghbi HY (2007) The story of RETT syndrome: from clinic to neurobiology. Neuron 56: 422-437
16. Charalambous M, da Rocha ST, Ferguson-Smith AC (2007) Genomic imprinting, growth control and the allocation of nutritional resources:
17. consequences for postnatal life. Curr Opin Endocrinol Diab Obes 14: 3-12
18. ChaumeilJ, Le Baccon P, Wutz A, Heard E (2006) A novel role forXist RNAin the formation of a repressive nuclear compartment into which genes are recruited when silenced. Genes Dev 20: 2223-2237
19. Chaumeil J, Okamoto I, Guggiari M, Heard E (2002) Integrated kinetics of X chromosome inactivation in differentiating embryonic stem cells.Genome Res 99: 75-84
20. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23
21. Csankovszki G, Panning B, Bates B, Pehrson JR, Jaenisch R (1999) Conditional deletion of Xist disrupts histone macroH2A localization but not maintenance of X inactivation. Nat Genet 22: 323-324
22. de Belle I, Cai S, Kohwi-Shigematsu T (1998) The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J Cell Biol 141: 335-348
23. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T (1992) A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 70: 631-645
24. Duret L, Chureau C, Samain S, Weissenbach J, Avner P (2006) The Xist RNAgene evolved in eutherians by pseudogenization of a protein-coding gene. Science (New York, NY) 312: 1653-1655
25. Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science (New York, NY) 300: 455
26. Favier R, Lavergne JM, Costa JM, Caron C, Mazurier C, Viemont M, Delpech M, ValleixS (2000) Unbalanced X-chromosome inactivation with a novel FVIII gene mutation resulting in severe hemophilia A in a female. Blood 96:43734375
27. Gal-Yam EN, Saito Y, Egger G, Jones PA (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59: 267-280
28. Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, et al (2002) BRCA1 supportsXIST RNA concentration on the inactive X chromosome. Cell 111: 393-405
29. Gibbons RJ, Picketts DJ, Villard L, Higgs DR (1995) Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell 80: 837-845
30. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of RETT syndrome. Science (New York, NY) 315:1143-1147
31. Hall LL, Byron M, Sakai K, Carrel L, Willard HF, Lawrence JB (2002) An ectopic human XIST gene can induce chromosome inactivation in postdifferentiation human HT-1080 cells. Proc Natl Acad Sci USA 99: 86778682
32. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T (2008) SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452: 187-193
33. Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, Gartler SM (1999) The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci USA 96: 1441214417
34. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE (2009) BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 28: 3022-3032
35. Huang KC, Rao PH, Lau CC, Heard E, Ng SK, Brown C, Mok SC, Berkowitz RS, Ng SW (2002) Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther 1: 769-776
36. Huppke P, Maier EM, Warnke A, Brendel C, Laccone F, Gartner J (2006) Very mild cases of RETT syndrome with skewed X inactivation. J Med Genet 43:814-816
37. Iacobuzio-Donahue CA (2009) Epigenetic changes in cancer. Annu Rev Pathol 4: 229-249
38. Invernizzi P, Pasini S, Selmi C, Miozzo M, Podda M (2008) Skewing of X chromosome inactivation in autoimmunity. Autoimmunity 41: 272-277
39. Kawakami T, Okamoto K, Ogawa O, Okada Y (2004a) XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer.Lancet 363: 40-42
40. Kawakami T, Okamoto K, Sugihara H, Hattori T, Reeve AE, Ogawa O, Okada Y (2003) The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors. J Urol 169: 1546-1552
41. Kawakami T, Zhang C, Taniguchi T, Kim CJ, Okada Y, Sugihara H, Hattori T, Reeve AE, Ogawa O, Okamoto K (2004b) Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene 23: 6163-6169
42. Keohane AM, O'Neill LP, Belyaev ND, Lavender JS, Turner BM (1996) X- Inactivation and histone H4 acetylation in embryonic stem cells. Dev Biol 180: 618-630
43. Kishino T, Lalande M, Wagstaff J (1997) UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 15: 70-73
44. Laird PW,Jaenisch R (1996) The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet 30: 441-464
45. LanerT, Schulz WA, Engers R, Muller M, Florl AR (2005) Hypomethylation of the XIST gene promoter in prostate cancer. Oncol Res 15: 257-264
46. Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260
47. Leung C, Lingbeek M, Shakhova O, Liu J,Tanger E, Saremaslani P, Van Lohuizen M, Marino S (2004) Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428: 337-341
48. LexnerMO, Bardow A,Juncker I,Jensen LG, Almer L, KreiborgS, HertzJM (2008) X-linked hypohidrotic ectodermal dysplasia. Genetic and dental findings in 67 Danish patients from 19 families. Clin Genet 74: 252-259
49. Liedtke M, Cleary ML (2009) Therapeutic targeting of MLL. Blood 113: 60616068
50. Lind GE, Skotheim RI, Lothe RA (2007) The epigenome of testicular germ cell tumors. APMIS 115: 1147-1160
51. Looijenga LH, Gillis AJ, van Gurp RJ, Verkerk AJ, Oosterhuis JW (1997) X inactivation in human testicular tumors. XIST expression and androgen receptor methylation status. Am J Pathol 151: 581-590
52. Lucchesi JC, Kelly WG, Panning B (2005) Chromatin remodeling in dosagecompensation. Annu Rev Genet 39: 615-651
53. Mak W, Nesterova TB, de Napoles M, Appanah R, Yamanaka S, Otte AP, Brockdorff N (2004) Reactivation of the paternal X chromosome in early mouse embryos. Science (New York, NY) 303: 666-669
54. Malcolm S, Clayton-Smith J, Nichols M, Robb S, Webb T, Armour JA, Jeffreys AJ, Pembrey ME (1991) Uniparental paternal disomy in Angelman's syndrome. Lancet 337: 694-697
55. Marahrens Y, Panning B, Dausman J, Strauss W, Jaenisch R (1997) Xist-deficient mice are defective in dosage compensation but not spermatogenesis. Genes Dev 11: 156-166
56. Matsuura T, SutcliffeJS, Fang P, Galjaard RJ,Jiang YH, Benton CS, RommensJM, Beaudet AL (1997) De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 15: 74-77
57. McDonald HL, Gascoyne RD, Horsman D, Brown CJ (2000) Involvement of the X chromosome in non-Hodgkin lymphoma. Genes Chromosomes Cancer 28:246-257
58. Morleo M, Franco B (2008) Dosage compensation of the mammalian X chromosome influences the phenotypic variability of X-linked dominant male-lethal disorders. J Med Genet 45: 401-408
59. Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M (1989) Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature 342: 281-285
60. Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, Tohonen V, Hedborg F, Schofield P, Flam F, Ekstrom TJ (1993) IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet 4: 94-97
61. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, et al (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242
62. Okamoto I,Otte AP, Allis CD, Reinberg D, Heard E (2004) Epigenetic dynamics of imprinted X inactivation during early mouse development. Science (New York, NY) 303: 644-649
63. Pageau GJ, Hall LL, Lawrence JB (2007) BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin. J Cell Biochem 100: 835-850
64. Pavan Kumar, P, PurbeyPK, Sinha CK, Notani D, Limaye A, Jayani RS, Galande S (2006) Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Mol Cell 22: 231-243
65. Penny GD, Kay GF, Sheardown SA, Rastan S, Brockdorff N (1996) Requirement for Xist in X chromosome inactivation. Nature 379: 131-137
66. Purbey PK, Singh S, Notani D, Kumar PP, Limaye AS, Galande S (2009) Acetylation-dependent interaction of SATB1 and CtBP1 mediates transcriptional repression by SATB1. Mol Cell Biol 29: 1321-1337
67. Rastan S, Robertson EJ (1985) X-chromosome deletions in embryo-derived (EK) cell lines associated with lack ofX-chromosome inactivation. J Embryol Exp Morphol 90: 379-388
68. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S (2006) Xchromosomal abnormalities in basal- like human breast cancer. Cancer cell 9: 121-132
69. Richon VM (2008) A new path to the cancer epigenome. Nat Biotechnol 26: 655-656
70. Ringrose L, Paro R (2007) Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development (Cambridge, England) 134: 223-232
71. Sahoo T, del Gaudio D, German JR, Shinawi M, Peters SU, Person RE, Garnica A, Cheung SW, Beaudet AL (2008) Prader-Willi phenotype caused by paternal deficiency for the HBII-85C/D box small nucleolar RNA cluster. Nat Genet 40: 719-721
72. Savarese F, Flahndorfer K, Jaenisch R, Busslinger M, Wutz A (2006) Hematopoietic precursor cells transiently reestablish permissiveness for X inactivation. Mol Cell Biol 26: 7167-7177
73. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G (2007) Genome regulation by polycomb and trithorax proteins. Cell 128: 735-745
74. Schwartz YB, Pirrotta V (2008) Polycomb complexes and epigenetic states. Curr Opin Cell Biol 20: 266-273
75. Sirchia SM, Tabano S, Monti L, Recalcati MP, Gariboldi M, Grati FR, Porta G, Finelli P, Radice P, Miozzo M (2009) Misbehaviour of XIST RNA in breast cancer cells. PLoS One 4: e5559
76. Sun BK, Tsao H (2008) X-chromosome inactivation and skin disease. J Invest Dermatol 128: 2753-2759
77. Takagi N, Sugawara O, Sasaki M (1982) Regional and temporal changes in the pattern of X-chromosome replication during the early post-implantation development of the female mouse. Chromosoma 85: 275-286
78. Talebizadeh Z, Bittel DC,VeatchOJ, Kibiryeva N, Butler MG (2005) Brief report: non-random X chromosome inactivation in females with autism. J Autism Dev Disord 35: 675-681
79. Tan JA, Sun Y, Song J, Chen Y, Krontiris TG, Durrin LK (2008) SUMO conjugation to the matrix attachment region-binding protein, special AT-rich sequence- binding protein-1 (SATB1), targets SATB1 to promyelocytic nuclear bodies where it undergoes caspase cleavage. J Biol Chem 283: 18124-18134
80. Tiwari VK, McGarvey KM, Licchesi JD, Ohm JE, Herman JG, Schubeler D, Baylin SB (2008) PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol 6: 2911-2927
81. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM (2007) Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52: 455-463
82. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ,Sewalt RG, Otte AP, etal (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629
83. Vincent-Salomon A, Ganem-Elbaz C, Manie E, Raynal V, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH, Heard E (2007) X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors. Cancer Res 67: 5134-5140
84. Wutz A (2007) Xist function: bridging chromatin and stem cells. Trends Genet 23: 457-464
85. Wutz A, Jaenisch R (2000) A shift from reversible to irreversible X inactivation is triggered during ES cell differentiation. Mol Cell 5: 695-705
86. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T (2002) SATB1 targets chromatin remodelling to regulate genes over long distances. Nature 419: 641-645